Reza Zahiri, PhD, MBA’s Post

#ProudToBeBostonScientific Boston Scientific has grown to become one of the largest medical technology companies in the world. This transformation has required visionary leadership and a remarkable ability to adapt. Each CEO has played a crucial role in the company's growth. Strategic acquisitions have been critical to Boston Scientific's growth. Although some presented challenges, they allowed the company to expand and strengthen its position in the market. The ability to adapt to significant changes, including financial crises, has been key to its success. Mike Mahoney's strategy of focusing on organic growth and improving company culture has resulted in a significant increase in market valuation. Restoring the confidence of investors, regulators and customers has been a priority, ensuring long-term stability and growth. Improving culture and values has been essential to attract and retain talent, and to improve the company's reputation in the market. All of the above is an example of the importance of leadership, the ability to adapt and the combination of organic growth with strategic acquisitions. Thanks to Reza Zahiri, PhD, MBA to share this valuable information. #MedTech #Leadership #Innovation #BusinessGrowth #BostonScientific #BusinessStrategy

🚀 J&J's bold medtech vision: is $30B just the beginning? Johnson & Johnson's staggering $30B injection into medtech acquisitions tells us one thing - they're here to play the long game. With impressive Q1 sales of $7.82B showing a steady 4.5% year-on-year growth, J&J's strategic moves are more than just shots in the dark. 💡 The recent acquisition spree including trailblazers like Abiomed, with sales soaring to $371M from $324M last year, shows just how serious J&J is about revolutionizing cardiac care. CEO Joaquin Duato's unwavering commitment to long-term, sector-agnostic M&A pursuits spells an exciting future for industry innovators and the wider public. J&J isn't just thinking growth; they're thinking legacy. 🌱 By eyeing the high-margin, high-impact areas, like cardiovascular tech - where the needs are great and ripe for breakthroughs - they're not only expanding their empire but raising the bar for patient care. It's not just about being a big player; it's about being the right player in the right space at the right time.💼 For those shaping the future at the helm of tech in MedTech, pharma, and BioTech, or those who orchestrate the symphony of executive decision-making - let's talk. This is where foresight meets execution, and where your expertise can become part of a larger narrative. For my fellow HealthTech leaders, how do we see our roles evolving in this transformative era? Drop a comment, let's engage. 💬 #Healthtech #Innovation #JNJ

3 #MedTech Spinoffs That Reshaped the Industry in 2023, and What to Expect Next: GE HealthCare, Johnson & Johnson, and Danaher Corporation completed transactions this year. Baxter International Inc., 3M, and Medtronic are now on deck. Corporate spinoffs are redefining the #medicaltechnology sector, as executives look to sharpen the focus of their operations, boost revenue and profit, and improve investor returns. Parent companies are taking aim at the “conglomerate discount,” a phenomenon where large organizations are valued at less than the sum of their component businesses, said Jim Welch global medtech leader at consulting firm Ernst & Young. While spinoffs tend to underperform the market in their first year, they outperform over a three- to five-year timeframe, according to a recent analysis by EY and Goldman Sachs that looked at the transactions across a range of industries. “We’ve seen a lot of critical thinking about portfolio and capital allocation that’s really come to the forefront now,” Welch said in an interview. Newly separated companies also tend to be active on the M&A front. “They have their own capital in place, and they can make their own decisions,” he said. “That’s definitely a lever that we see them pull right out of the gate.”

📢KKR, Carlyle, EQT, Others in Race to Acquire Healthium ⚡ Top global private equity firms, including EQT (formerly BPEA EQT), KKR, Carlyle, Hillhouse, and TA Associates are competing against each other to acquire Healthium Medtech, the leading surgical sutures and needles manufacturer. ⚡The Apax Partners-promoted Healthium Medtech is also the largest manufacturer of surgical needles globally by volume, making it the fiercest bidding process of the year. ⚡Reportedly, Bain Capital and Advent International are also in the running, heightening competition in this high-stakes deal. ⚡These funds were shortlisted this weekend after the first round of screening based on non-binding bids submitted last weekend. The bidding war, expected to value the company at INR 6300 Cr to INR 6500 Cr, marks a significant acquisition opportunity in the medical devices sector. Healthium Medtech Limited KKR & Co. L.P., Investment Banking Arm EQT Ventures #Acquisitions #DHN Digital Health News Bain Capital Advent International Apax 📌Read More: https://lnkd.in/gTm-gg4e

3 medtech spinoffs that reshaped the industry in 2023, and what to expect next Corporate spinoffs are redefining the medical technology sector, as executives look to sharpen the focus of their operations, boost revenue and profit, and improve investor returns. While spinoffs tend to underperform the market in their first year, they outperform over a three- to five-year timeframe. GE Healthcare, Johnson & Johnson and Danaher completed transactions this year. Baxter, 3M and Medtronic are now on deck. #medtech #medtechspinoffs #spinoffs #medtechindustry

We've been writing a lot about medtech spinoffs in the last two years. Sometimes it's hard to keep track of all of them! Thankfully, my colleague Susan Kelly recapped what some of the recent spinoffs, including GE HealthCare and Johnson & Johnson's Kenvue, mean for the industry, and three more planned transactions to watch. https://lnkd.in/dp53nHf5

**Johnson & Johnson Q1 2024: Strong Start with Strategic Acquisitions Driving Growth 🚀** Q1 2024 has been robust for J&J, with earnings surpassing expectations at $2.71 per share, a 7 cent beat. Sales hit $21.4 billion, marking a 2.3% increase. The MedTech division shone with $7.8 billion in revenue, growing by 4.5%. The acquisition of Shockwave Medical strengthens J&J’s cardiovascular tech portfolio, promising enhanced long-term growth [oai_citation:1,J&J could reach market-leading medtech growth after consumer spinoff: analysts | MedTech Dive](https://lnkd.in/e5GbidJN). #HealthcareInnovation #MedTech #EarningsReport

#NYC-based #Investment Firm #EQT Private Equity #Acquired #Zeus from the Tourville family. Founded in 1966, Zeus is a pioneer in the design, development, and extrusion of #fluoropolymer tubing for medical devices and select industrial applications. EQT also announced that John Groetelaars, former CEO of Hillrom and EQT #Industrial Advisor, will serve as Zeus’ Executive Chairman upon closing of the transaction. For more than 50 years, Zeus has delivered innovative and mission-critical components that improve the #efficacy and performance of highly #complex catheters, which are used in life saving, #minimally invasive medical procedures, among other applications. Zeus’ components enable the delivery of minimally invasive #interventional procedures, which drive significantly better health outcomes than #traditional open #surgeries, including faster #patient recovery and reduced pain, at lower cost. EQT will support Zeus with investments in additional capacity, R&D, and operational excellence, to support the rapidly growing #medical fields that #leverage minimally invasive technologies. EQT Group Zeus Industrial Products, Inc. John Groetelaars Ethan Waxman Steve Peterson Eric Liu #eqt #zeus #acquisition #startup

How does Johnson & Johnson aim to sustain its growth and strategic focus amidst its aggressive acquisitions and changing medtech landscape?   Johnson & Johnson isn't just making waves in the medtech industry; it's orchestrating a symphony of innovation and growth. With Q1 sales surging to a formidable $7.82 billion and cardiovascular sales skyrocketing to $1.81 billion (roughly 20% YoY growth), the numbers speak volumes about J&J's strategic prowess. And let's not forget Abiomed, whose sales jumped to $371 million compared with $324 million in the previous year—a clear indication of momentum.   But what's driving this meteoric rise? One needs only to examine J&J's aggressive acquisition strategy, which has seen the healthcare giant shell out over $30 billion on medtech assets alone in just two years. CEO Joaquin Duato's unwavering commitment to growth underscores the company's long-term vision, with M&A remaining a key priority aimed at driving innovation and enhancing patient care standards.   At the heart of J&J's strategy lies a focused effort on cardiovascular innovation, exemplified by acquisitions like Abiomed and Shockwave Medical. These strategic moves have already paid dividends, with the cardiovascular segment experiencing remarkable growth, particularly in electrophysiology, which saw a staggering 23% year-over-year increase to reach $1.34 billion in sales for the quarter. J&J's pursuit of high-growth markets with groundbreaking technologies sets the stage for even more remarkable feats in the world of medtech.   https://lnkd.in/gX6Di4nv #MedTechNews #MedicalDevices #HealthcareInnovation #MedTechIndustry #HealthTech #HealthcareTechnology #MedDeviceNews #HealthcareNews #MedTechTrends